Načítá se...
Rationale for azithromycin in COVID-19: an overview of existing evidence
Azithromycin has rapidly been adopted as a repurposed drug for the treatment of COVID-19, despite the lack of high-quality evidence. In this review, we critically appraise the current pharmacological, preclinical and clinical data of azithromycin for treating COVID-19. Interest in azithromycin has b...
Uloženo v:
| Vydáno v: | BMJ Open Respir Res |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
BMJ Publishing Group
2021
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7811960/ https://ncbi.nlm.nih.gov/pubmed/33441373 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjresp-2020-000806 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|